FPGS: A Potential Drug Target and Biomarker for NASH and Type 2 Diabetes

Target Name: FPGS

NCBI ID: G2356

FPGS

FPGS: A Potential Drug Target and Biomarker for NASH and Type 2 Diabetes

FPGS, or Folylpolyglutamate synthase, is a protein that is synthesized in the liver and is involved in the production of a type of glucose called polyglutamate. Polyglutamate is a key fuel source for the liver and other tissues, and it is involved in a wide range of physiological processes in the body.

One of the things that makes FPGS an interesting potential drug target is its role in the development of certain diseases. For example, FPGS is often elevated in individuals with non-alcoholic steatohepatitis (NASH), a type of liver disease that is characterized by the buildup of fat in the liver. In addition, FPGS has also been shown to be elevated in individuals with type 2 diabetes, a disease that is characterized by high levels of blood glucose.

Another potential mechanism by which FPGS may be involved in the development of certain diseases is its role in inflammation. FPGS has been shown to be involved in the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases.

FPGS is also of interest as a potential biomarker for certain diseases. For example, studies have shown that FPGS levels can be used as a diagnostic marker for NASH, and that they may also be elevated in individuals with type 2 diabetes. Additionally, FPGS has been shown to be involved in the regulation of cellular processes that are important for the development and progression of certain diseases, such as cancer.

In addition to its potential as a drug target and biomarker, FPGS is also of interest as a potential source of new therapies for certain diseases. For example, studies have shown that FPGS can be targeted with small molecules that inhibit its activity, and that these small molecules may have potential as treatments for NASH and type 2 diabetes.

Overall, FPGS is a protein that is involved in a wide range of physiological processes in the body, and it is of interest as a potential drug target and biomarker for certain diseases. Further research is needed to fully understand its role in these processes and to develop new treatments for those who are affected by NASH and type 2 diabetes.

Protein Name: Folylpolyglutamate Synthase

Functions: Catalyzes conversion of folates to polyglutamate derivatives allowing concentration of folate compounds in the cell and the intracellular retention of these cofactors, which are important substrates for most of the folate-dependent enzymes that are involved in one-carbon transfer reactions involved in purine, pyrimidine and amino acid synthesis. Unsubstituted reduced folates are the preferred substrates. Metabolizes methotrexate (MTX) to polyglutamates

The "FPGS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FPGS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets